Sparse pipeline for acromegaly and gigantism treatment limiting market growth

The acromegaly and gigantism treatment market will expand at a modest compound annual growth rate (CAGR) of 3.74% from around $588 million in 2013 to $707 million by 2018, limited by a sparse pipeline, according to a new study.

Research and consulting firm GlobalData’s latest report states that across six major markets (the USA, UK, France, Spain, Germany and Italy), Novartis’ (NOVN: VX) Sandostatin LAR Depot (octreotide acetate for injectable suspension), which is the current standard of care, will remain the dominant treatment throughout the forecast period.

Novartis’ Signifor LAR (pasireotide) was approved in both the European Union and the USA in fourth-quarter 2014 (The Pharma Letters December 16 and November 25, 2014) and there are now only two drugs in late-stage development, namely Chiasma’s oral octreotide and Antisense Therapeutics’ ATL1103.